TSLPR:TSLP [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit
The TSLPR:TSLP [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling antibodies that block the binding between TSLPR (thymic stromal lymphopoietin receptor) and TSLP. This kit comes in a convenient 96-well format, with enough recombinant human biotin-labeled TSLP (amino acids 29-159), human TSLP-R (amino acids 25-231), streptavidin-HRP, and assay buffer for 100 reactions.
Figure 1: Illustration of the mechanism of TSLPR: TSLP [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit.
A 96-well plate is coated with TSLPR protein. After blocking, the plate is pre-incubated with a neutralizing antibody. After incubation with Biotin-TSLP, the plate is washed and Streptavidin-HRP is added. The ELISA ECL substrate is added and the resulting signal can be measured using a chemiluminescence microplate reader. The chemiluminescence signal is proportional to the binding of TSLPR to TSLP.
Need us to run inhibitor screens or profile your compounds against TSLPR:TSLP binding? Check out our Immunotherapy Biochemical Screening Service.
- 1x PBS buffer (Phosphate Buffer Saline, pH 7.4)
- PBS-T (1x PBS buffer with 0.05% Tween-20)
- Microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| 102169 | TSLP, Avi-Tag, His-Tag, Biotin-Labeled* | >1 µg | -80°C |
| 102163 | TSLPR, Fc-Tag* | 20 µg | -80°C |
| 82620 | 5x PP-02 Buffer | 4 ml | -20°C |
| 82719 | Blocking Buffer 7 | 40 ml | +4°C |
| 79742 | Streptavidin-HRP | 10 µl | +4°C |
| 79670 | ELISA ECL Substrates A (translucent bottle) | 6 ml | Room Temp |
| ELISA ECL Substrates B (brown bottle) | 6 ml | Room Temp | |
| 79699 | White 96-well microplate | 1 | Room Temp |
*The initial concentration of both TSLP-R and TSLP is lot-specific and will be indicated on the tube containing the protein.
TSLP (thymic stromal lymphopoietin) is a protein that functions as a type I cytokine, as an alarmin and growth factor in the immune system. It is involved in type 2 immune responses, TH2 (T helper 2 cells) responses, and the maturation and recruitment of dendritic cells (DCs), T cells, B cells, neutrophils, mast cells, and other lymphoid cells. It can be produced by epithelial and stromal cells in lung, skin, and gastric system, but also by DCs, basophils and mast cells. Its expression can be induced by infections, pro-inflammatory cytokines, proteases, and even mechanical injury. For instance, it can be produced in the lungs in response to infection with influenza or rhinovirus. Its role as alarmin can result in increasing inflammation. TSLP is linked to allergic reactions such as asthma, atopic dermatitis, and food allergies, by inducing the expression of OX40L, CD80 and CD86 and stimulating CD4+ T cells. In 2021, the TLSP-neutralizing antibody tezepelumab was approved for the treatment of severe asthma. Targeting TSLP is an active area of investigation with ongoing clinical trials for the treatment of autoimmune disorders.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.